JP2022507744A5 - - Google Patents
Info
- Publication number
- JP2022507744A5 JP2022507744A5 JP2021527213A JP2021527213A JP2022507744A5 JP 2022507744 A5 JP2022507744 A5 JP 2022507744A5 JP 2021527213 A JP2021527213 A JP 2021527213A JP 2021527213 A JP2021527213 A JP 2021527213A JP 2022507744 A5 JP2022507744 A5 JP 2022507744A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant mva
- herv
- mva
- pharmaceutical composition
- cancerous tumors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18207238 | 2018-11-20 | ||
| EP18207238.9 | 2018-11-20 | ||
| US201962807720P | 2019-02-19 | 2019-02-19 | |
| US62/807,720 | 2019-02-19 | ||
| PCT/EP2019/081942 WO2020104531A1 (en) | 2018-11-20 | 2019-11-20 | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507744A JP2022507744A (ja) | 2022-01-18 |
| JP2022507744A5 true JP2022507744A5 (cg-RX-API-DMAC7.html) | 2022-10-26 |
| JP7625518B2 JP7625518B2 (ja) | 2025-02-03 |
Family
ID=68542659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527213A Active JP7625518B2 (ja) | 2018-11-20 | 2019-11-20 | ４－１ｂｂｌ（ｃｄ１３７ｌ）及び／またはｃｄ４０ｌをコードする組み換えｍｖａの腫瘍内及び／または静脈内投与によって、がんを治療する療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12390515B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3883599A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7625518B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210094535A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113056284A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019385665B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021009856A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3119503A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL283187A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021005560A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202104918PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020104531A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111050790B (zh) * | 2017-08-24 | 2024-07-12 | 巴法里安诺迪克有限公司 | 通过静脉内施用重组mva和抗体治疗癌症的组合疗法 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| US20230190922A1 (en) * | 2019-11-20 | 2023-06-22 | Bavarian Nordic A/S | Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer |
| IL293012A (en) * | 2019-11-20 | 2022-07-01 | Bavarian Nordic As | Medicinal uses of 4-1bbl modified ankara virus vaccinia ((recombinant mva |
| US20230174653A1 (en) * | 2020-04-06 | 2023-06-08 | St. Jude Children's Research Hospital, Inc. | B7-h3 chimeric antigen receptors |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| WO2023076768A1 (en) * | 2021-10-26 | 2023-05-04 | Navicure Biopharmaceuticals Limited | Combination therapies against cancer and infectious diseases |
| WO2023118508A1 (en) * | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| EP4452306A1 (en) | 2021-12-23 | 2024-10-30 | Bavarian Nordic A/S | Therapy for modulating immune response with recombinant mva encoding il-12 |
| CN117004579B (zh) * | 2023-06-29 | 2024-11-15 | 苏州恩立维生物科技有限公司 | 重组溶瘤牛痘病毒及其应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| DE69435171D1 (de) | 1993-09-14 | 2009-01-08 | Pharmexa Inc | Pan dr-bindeproteinen zur erhöhung der immunantwort |
| AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
| US6969609B1 (en) * | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| SK4272001A3 (en) | 1998-10-05 | 2003-02-04 | Pharmexa As | Methods for therapeutic vaccination |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| DE60235041D1 (de) | 2001-11-30 | 2010-02-25 | Us Gov Health & Human Serv | Und ihre verwendung |
| EP2345665A3 (en) | 2001-12-04 | 2012-02-15 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| DK2029756T3 (en) | 2006-06-20 | 2017-02-13 | Transgene Sa | PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS |
| NZ592082A (en) | 2008-11-27 | 2013-03-28 | Bavarian Nordic As | Promoters for recombinant viral expression |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| EP2800762B1 (en) | 2012-01-03 | 2018-01-03 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Native and agonist ctl epitopes of the muc1 tumor antigen |
| WO2013189611A1 (en) | 2012-06-22 | 2013-12-27 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| WO2014037124A1 (en) * | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| EP2908851A1 (en) | 2012-10-19 | 2015-08-26 | Bavarian Nordic Inc. | Methods and compositions for the treatment of cancer |
| EP2912183B1 (en) | 2012-10-28 | 2020-05-06 | Bavarian Nordic A/S | Pr13.5 promoter for robust t-cell and antibody responses |
| KR102499737B1 (ko) * | 2014-05-13 | 2023-02-13 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법 |
| KR20150135148A (ko) | 2014-05-23 | 2015-12-02 | 주식회사 제넥신 | Pd-l1 융합 단백질 및 이의 용도 |
| EP4523756A3 (en) | 2015-02-13 | 2025-05-28 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| ES2901468T3 (es) | 2015-07-31 | 2022-03-22 | Bavarian Nordic As | Promotores para mejorar la expresión en poxvirus |
| IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| WO2018161092A1 (en) * | 2017-03-03 | 2018-09-07 | New York University | Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins |
-
2019
- 2019-11-20 CA CA3119503A patent/CA3119503A1/en active Pending
- 2019-11-20 SG SG11202104918PA patent/SG11202104918PA/en unknown
- 2019-11-20 KR KR1020217014706A patent/KR20210094535A/ko active Pending
- 2019-11-20 WO PCT/EP2019/081942 patent/WO2020104531A1/en not_active Ceased
- 2019-11-20 CN CN201980076127.2A patent/CN113056284A/zh active Pending
- 2019-11-20 AU AU2019385665A patent/AU2019385665B2/en active Active
- 2019-11-20 JP JP2021527213A patent/JP7625518B2/ja active Active
- 2019-11-20 BR BR112021009856A patent/BR112021009856A8/pt unknown
- 2019-11-20 US US17/295,384 patent/US12390515B2/en active Active
- 2019-11-20 EP EP19802224.6A patent/EP3883599A1/en active Pending
- 2019-11-20 MX MX2021005560A patent/MX2021005560A/es unknown
-
2021
- 2021-05-13 IL IL283187A patent/IL283187A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022507744A5 (cg-RX-API-DMAC7.html) | ||
| Leoni et al. | A genetic vaccine encoding shared cancer neoantigens to treat tumors with microsatellite instability | |
| Bilusic et al. | Immunotherapy of prostate cancer: facts and hopes | |
| Schlom | Therapeutic cancer vaccines: current status and moving forward | |
| CN109219445B (zh) | 嵌合抗原受体修饰细胞治疗癌症的应用 | |
| JP2023052263A (ja) | 腫瘍形質導入のための組成物及び方法 | |
| AU2019385665B2 (en) | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-ibbl (cd137l) and/or cd40l | |
| JP2017515841A5 (cg-RX-API-DMAC7.html) | ||
| JP2017515837A5 (cg-RX-API-DMAC7.html) | ||
| JP2023510651A (ja) | 修飾された免疫細胞及びその使用 | |
| JP2023503857A5 (cg-RX-API-DMAC7.html) | ||
| JP2020508662A (ja) | 腫瘍形質導入のための組成物及び方法 | |
| JP2019506428A5 (cg-RX-API-DMAC7.html) | ||
| Chang et al. | Vaccinating against cancer: getting to prime time | |
| JP2026010064A (ja) | 癌ワクチン | |
| JP2023503858A5 (cg-RX-API-DMAC7.html) | ||
| Berraondo et al. | Immunogenicity and efficacy of personalized adjuvant mRNA cancer vaccines | |
| CN114867491A (zh) | 用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒 | |
| Hussain et al. | Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials | |
| De Mare et al. | Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition | |
| Kamel et al. | Advancement insights in cancer vaccines: mechanisms, types, and clinical applications | |
| JP2022542802A5 (cg-RX-API-DMAC7.html) | ||
| GB2607723A (en) | Vector for cancer treatment | |
| Yamasaki et al. | Tumor epitope spreading by a novel multivalent therapeutic cellular vaccine targeting cancer antigens to invariant NKT-triggered dendritic cells in situ | |
| RU2021117499A (ru) | Терапия для лечения рака с помощью внутриопухолевого и/или внутривенного введения рекомбинантного mva, кодирующего 4-1bbl (cd137l) и/или cd40l |